Glaxo's 2008 earnings take a hit of $400 million from a settlement of a five year investigation by the US attorney's office in Colorado and the US Attorney's office in Massachusetts. The investigation was about the manner in which Glaxo marketed its antidepressant drug Paxil and the drug Wellbutrin SR. Glaxo is said to have promoted the depressants for off-label uses. This follows settlements of $2.3 billion by Pfizer for off-label promotion of painkiller Bextra. Eli Lilly settled with $1.4 billon for similiar charges on antipsychotic medicine Zyprexa.